AFWG shall not bear any responsibility for any content on such sites. Any link to a third-party site does not constitute an endorsement of the third party, their site or services. AFWG also makes no warranties as to the content of such sites.
Would you like to continue?
 | Don’t show me this again. |
Dr Stephen Sheng-Fong Lin is a distinguished medical professional with extensive experience in managing medical affairs and leading educational initiatives in the field of infectious diseases, with a particular focus on fungal infections. Dr Lin plays a crucial role in shaping healthcare communities across multiple locations in Asia, including Taiwan, Hong Kong, and Singapore, among others as his ex-career in industry.
Dr Lin’s career highlights include over 19 years of experience in the pharmaceutical industry, coupled with 13 years of clinical practice, including 5 years as the Chief of the Infectious Disease Department. He has a proven track record in driving antimicrobial stewardship (AMS) initiatives across Asia, contributing to the responsible use of antimicrobial agents through the development of local strategies and the establishment of centers of excellence for AMS training. His leadership has been instrumental in securing marketing authorization for key anti-infective products such as Tygacil, Zyvox, Zavicefta, Eraxis/Ecalata, and Cresemba, which have significantly impacted patient care in the region.
In addition to his role in product development and regulatory affairs, Dr Lin has led many key initiatives in advancing medical education, specifically in infectious diseases, and successfully established and expanded the Asia Key Opinion Leader (KOL) network, including Asia Fungal Working Group in 2009, which was affiliated with ISHAM since 2013, and AMW Working Group in 2017, facilitating high-quality patient care and fostering collaboration across the region. Dr Lin’s dedication to education is further exemplified by his involvement in sponsoring for creating the AMS Blueprint, a critical resource for implementing AMS systems in hospitals, and the Project MMTN, a training program to enhance the quality, capability, and capacity for fungal infections management across Asia.
Dr Lin’s expertise and leadership continue to drive advancements in the management of infectious diseases and fungal infections, making him a key figure in both the pharmaceutical industry and the broader medical community in Asia.
 | 真菌学交流平台 |
